{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"mCR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Complete cytogenetic response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Partial cytogenetic response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"HI of at least 1 lineage"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"HI of at least 1 lineage without CR or PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Number of participants with PR, mCR, SD, complete or partial cytogenetic response, and HI. PR: BMB \\>5% and decreased by ≥50% (at least 4 weeks), meeting all CR criteria if abnormal before treatment except BMB. mCR: BMB ≤5% and decreased by ≥50%. SD: failure to achieve PR, no evidence of progression. Complete or partial cytogenic response: disappearance of chromosomal abnormality without new ones, or ≥ 50% reduction of chromosomal abnormality. HI: erythroid response (pretreatment \\<11g/dL): hemoglobin increase by≥1.5 g/dL, relevant reduction of units of red blood cell transfusions by at least 4 transfusions/8 weeks compared to pretreatment transfusion number in previous 8 weeks; platelet response (pretreatment \\<1x10\\^11/L): increase of ≥30x10\\^9/L if starting with \\>20x10\\^9/L, and increase from \\<20x10\\^9/L to \\>20x10\\^9/L and by at least 100%; neutrophil response (pretreatment \\<1x10\\^9/L): at least a 100% increase, absolute increase \\>0.5x10\\^9/L.","groups":[{"description":"Participants received SC or IV administration of azacitidine at the starting dose of 75 mg/m2/day for 7 days every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD.","id":"OG000","title":"MDS Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The full analysis population included all participants who received at least 1 dose of any study treatment.","reportingStatus":"POSTED","timeFrame":"maximum of 34 months","title":"Number of Participants With Disease-Specific Efficacy Measures in the MDS Cohort","type":"SECONDARY","unitOfMeasure":"Participants"}